Marinus Pharmaceuticals Inc

Marinus Pharmaceuticals — Technical Presentation (September 2019)

13 slides from Marinus Pharmaceuticals's technical presentation, Sep 26, 2019

  1. Slide 1: Safe Harbor Statement

    Safe Harbor Statement To the extent that statements contained in this press release are not descriptions of historical facts regarding Marinus, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private

  2. Slide 2: Goals of a New Therapy for the Treatment of RSE

    Goals of a new treatment for RSE Prevent patient progression towards escalation of treatment (IV anesthetics) Rapid cessation of SE Maintenance of seizure control over study period Goals of a New Therapy for the Treatment of RSE Benzodiazepine Administered Medically induced Coma Established Status E

  3. Slide 3: Refractory Status Epilepticus is a Neurological Emergency

    Mortality Overall mortality is ~17-39% in RSE patients3,7 Mean RSE duration (in hrs.) between survivors and non-survivors was found to be 88.9 and 120.3 (p=0.002)3 Hospital stay Patients that achieve SE cessation within 1 or 12 hours (convulsive or non-convulsive SE, respectively) spent significantl

  4. Slide 4: Rationale for IV Ganaxolone for the Treatment of RSE

    Ganaxolone has demonstrated a broad range of anticonvulsant and psychotherapeutic responses Rationale for IV Ganaxolone for the Treatment of RSE Benzodiazepines are effective in treating acute seizures but not RSE Benzodiazepines are positive allosteric modulators of the synaptic (gamma subunit) GAB

  5. Slide 5: Study design: IV Ganaxolone in RSE patients

    Treatment Period Loading Dose Maintenance Taper Phase 2 RSE Trial Design Diagnosis of convulsive or non-convulsive SE Failed at least one 2nd line IV AED but not progressed to 3rd line IV anesthetics Bolus plus continuous infusion 2-4 day infusion 18 hour taper Screening Post-treatment Follow-up 24

  6. Slide 6: Baseline Characteristics

    17 patients 8 males, 9 females, Mean Age 56.9 years (range: 23 – 88) Varied reasons for RSE (e.g., brain tumors, vascular (stroke, hemorrhage), metabolic, autoimmune, alcohol withdrawal, illicit drug overdose) Types of SE 5 (29%) convulsive SE 11 (65%) non-convulsive, and 1 (6%) convulsive SE progre

  7. Slide 7: Efficacy of IV Ganaxolone

    Phase 2 RSE Trial – Efficacy of IV Ganaxolone 9 Cohort No escalation to IV anesthetics within 24 hours from infusion initiation (Primary Endpoint) Status-free at 24 hours from infusion initiation No escalation to additional IV AEDs or IV anesthetics for status relapse at any time through the follow

  8. Slide 8: Target Dose Provided Shorter ICU Time and Greater Improvements in CGI-I at Follow-up

    Target Dose Provided Shorter ICU Time and Greater Improvements in CGI-I at Follow-up 10 CGI-I at Final Follow-up Visit (Target Dose) 3: Minimally Improved N=1 2: Much Improved N=1 1: Very Much Improved N=5 *1 patient in Target Dose died due to perforated bowel (not related)

  9. Slide 9: IV Ganaxolone Safety Summary

    2 related in 2 patients 2 severe sedation 13 Related in 7 subjects 6 mild (2 hypotension, 2 somnolence, 1 urinary retention, 1 hypercarbia) 5 moderate (4 somnolence; 1 hypercarbia) 2 severe (2 sedation) Phase 2 RSE Trial - IV Ganaxolone Safety Summary 11 10 SAEs in 6 patients (also included in AEs)

  10. Slide 10: Status Epilepticus - U.S. Hospital Incidence

    Status Epilepticus - U.S. Hospital Incidence 75K Total SE Patients Annually in U.S. 23 unique ICD-10 codes with some reference to SE Refractory SE patient volumes range from 12.5K to 37.5K Minimum = patients coded as “intractable” in ICD-10 (understated) Maximum = 30%-50% of patients cited as refrac

  11. Slide 11: Conclusions

    No patients progressed to IV anesthetics during first 24 hours Median time to SE cessation = 5 minutes (n=15 evaluable) Durable response throughout study period in target dose cohort Patients failed mean of 2.1 second line IV AEDs Highly heterogeneous underlying cause of status Target patient popula

  12. Slide 12: Conclusions

    Phase 2 RSE Trial - Conclusions No patients progressed to IV anesthetics during fist 24 hours jy, Mecian me to SE cessaton = 5 minutes (15 evaluable) Durable response throughout study period in target dose cohort Patients failed mean of 2.1 second line IV AEDs Highly heterogeneous underlying cause o

  13. Slide 13: Thank You

    Thank You

Marinus Pharmaceuticals — Technical Presentation (September 2019) on 6ix